Aridis Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Aridis receives Nasdaq delisting notice; shares to trade on OTC Pink Sheets from July 19

Aridis Pharmaceuticals, Inc.

Nasdaq notified Aridis on July 17, 2023 that its common stock will be delisted from the Nasdaq Capital Market.
Delisting becomes effective at the opening of trading on July 19, 2023.
Company expects shares to trade on OTC Pink Sheets; will seek market makers to provide liquidity.
No assurance that an active trading market for shares will develop post-delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aridis Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

July 17, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) that it would delist the Company’s shares of common stock from the Nasdaq Capital Market upon the opening of trading on July 19, 2023. The Company’s common stock will be traded on the OTC Pink Sheets and the Company will seek to establish relationships with market makers to provide additional trading opportunities in the Company’s stock. However, there can be no assurance that a market for the Company’s shares will develop. - 2 - SIGNATURES Pursuan

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-024769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.